Hep C Race: Gilead Gets Poor Results, Novartis Jumps Into Game

Gilead has stumbled in the ongoing hepatitis C race with the relapse of most patients in one trial arm just a few weeks after ending treatment with GS-7977 — a recent pipeline acquisition. The news is a reversal from data the company shared in its fourth-quarter earnings call indicating those same patients had shown virtually no signs of the virus after four weeks of treatment. “Maybe there was a little more enthusiasm than there should have been,” John Milligan, Gilead’s president and chief operating officer, told analysts Feb. 17.
Clinical Trials Advisor